↓ Skip to main content
What is this page? Embed badge

Cancer Chemo- and Immunopharmacology

Overview of attention for book
Cover of 'Cancer Chemo- and Immunopharmacology'

Table of Contents

  1. Altmetric Badge
    Book Overview
  2. Altmetric Badge
    Chapter 1 General Progress in Clinical Chemotherapy of Advanced Disease
  3. Altmetric Badge
    Chapter 2 Adjuvant Therapies of Postsurgical Minimal Residual Disease
  4. Altmetric Badge
    Chapter 3 Limits of Animal Models in Cancer Chemotherapy
  5. Altmetric Badge
    Chapter 4 Clinical Chemotherapy: Its Correlation with Experimental Models
  6. Altmetric Badge
    Chapter 5 Metabolic Conversion of Methotrexate in Man
  7. Altmetric Badge
    Chapter 6 Biochemical Control of High-Dose Methotrexate/Leucovorin Rescue Therapy
  8. Altmetric Badge
    Chapter 7 High-Dose Methotrexate in Combination Chemotherapy for Small Cell Lung Cancer
  9. Altmetric Badge
    Chapter 8 Clinical and Laboratory Reevalution of Dichloromethotrexate
  10. Altmetric Badge
    Chapter 9 An Overview of the Clinical Pharmacology of N-Phosphonacetyl-L-Aspartate (PALA), a New Antimetabolite
  11. Altmetric Badge
    Chapter 10 N-(Phosphonacetyl)-L-Aspartate (PALA): Current Status
  12. Altmetric Badge
    Chapter 11 Synthesis, Biologic Effects, and Biochemical Properties of Some 2’-Azido- and 2’-Amino-2’-Deoxyarabinofuranosyl Pyrimidines and Purines
  13. Altmetric Badge
    Chapter 12 Prediction of Clinical Response to 5-Fluorouracil-Containing Chemotherapy: Preliminary Results of in Vitro Assay in Human Breast Cancer
  14. Altmetric Badge
    Chapter 13 Vindesine: A New Vinca Alkaloid
  15. Altmetric Badge
    Chapter 14 The Epipodophyllotoxin Derivatives VM-26 and VP-16-213, 1976–1979, a Review
  16. Altmetric Badge
    Chapter 15 Antitumor activity, pharmacology, and toxicity of ellipticines, ellipticinium, and 9-hydroxy derivatives: preliminary clinical trials of 2-methyl-9-hydroxy ellipticinium (NSC 264-137).
  17. Altmetric Badge
    Chapter 16 Comparative Pharmacokinetics of Chlorambucil and Melphalan in Man
  18. Altmetric Badge
    Chapter 17 Clinical Implications of Cisplatin Pharmacology
  19. Altmetric Badge
    Chapter 18 Cisplatinumdiamminodichloride (CPDD) in Chemotherapy of Cancers: A Phase II Therapeutic Trial
  20. Altmetric Badge
    Chapter 19 1,2-Diaminocyclohexane Platinum Derivatives of Potential Clinical Value
  21. Altmetric Badge
    Chapter 20 Preclinical and Phase I Studies of Malonatoplatinum
  22. Altmetric Badge
    Chapter 21 A Review of Clinical Studies of Pepleomycin
  23. Altmetric Badge
    Chapter 22 Experimental and Clinical Activity of a New Anthracycline Derivative: Detorubicin (14-Diethoxyacetoxydaunorubicin)
  24. Altmetric Badge
    Chapter 23 Clinical Study of Detorubicin
  25. Altmetric Badge
    Chapter 24 Preliminary clinical experience with 4-epidoxorubicin in advanced human neoplasia.
  26. Altmetric Badge
    Chapter 25 Quelamycin: A Summary of Phase I Clinical Trials
  27. Altmetric Badge
    Chapter 26 Current Status of Japanese Studies with the New Anthracycline Antibiotic Aclacinomycin A
  28. Altmetric Badge
    Chapter 27 Phase II Trial of Aclacinomycin in Acute Leukemia and Lymphosarcoma
  29. Altmetric Badge
    Chapter 28 Ultrastructural Study of the Cardiotoxicity and Light-Microscopic Findings of the Skin After Treatment of Golden Hamsters with Seven Different Anthracyclines
  30. Altmetric Badge
    Chapter 29 m-AMSA: A New Anticancer Agent
  31. Altmetric Badge
    Chapter 30 The rediscovery of DON (6-diazo-5-oxo-L-norleucine).
  32. Altmetric Badge
    Chapter 31 The Use of Peritoneal Dialysis for Delivery of Chemotherapy to Intraperitoneal Malignancies
  33. Altmetric Badge
    Chapter 32 The Development of Mesna for the Inhibition of Urotoxic Side Effects of Cyclophosphamide, Ifosfamide, and Other Oxazaphosphorine Cytostatics
  34. Altmetric Badge
    Chapter 33 Cell Kinetic Factors, Single Drugs and Combination
  35. Altmetric Badge
    Chapter 34 Hyperthermia and Chemotherapy: Preclinical Considerations
  36. Altmetric Badge
    Chapter 35 The Disposition of Intraperitoneal Bleomycin, Melphalan, and Vinblastine in Cancer Patients
  37. Altmetric Badge
    Chapter 36 Clinical Correlations of Drug Sensitivity in the Human Tumor Stem Cell Assay
  38. Altmetric Badge
    Chapter 37 Comments on the Carcinogenic, Mutagenic, and Teratogenic Properties of Anticancer Drugs
  39. Altmetric Badge
    Chapter 38 Long-Term Sequelae of Cancer Chemotherapy
Attention for Chapter 24: Preliminary clinical experience with 4-epidoxorubicin in advanced human neoplasia.
Altmetric Badge

Mentioned by

wikipedia
6 Wikipedia pages

Readers on

mendeley
18 Mendeley
Summary Wikipedia
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Preliminary clinical experience with 4-epidoxorubicin in advanced human neoplasia.
Chapter number 24
Book title
Cancer Chemo- and Immunopharmacology
Published in
Recent results in cancer research Fortschritte der Krebsforschung Progrès dans les recherches sur le cancer, January 1980
DOI 10.1007/978-3-642-81488-4_24
Pubmed ID
6934564
Book ISBNs
978-3-64-281490-7, 978-3-64-281488-4
Authors

V Bonfante, G Bonadonna, F Villani, A Martini, Bonfante, V., Bonadonna, G., Villani, F., Martini, A., V. Bonfante, G. Bonadonna, F. Villani, A. Martini

Abstract

4'-Epidoxorubicin (epi-DXR) was tested in 56 patients with various types of advanced malignancies. The pattern of acute toxicity was similar to that of doxorubicin (DXR), but epi-DXR produced a lower incidence of vomiting, stomatitis, alopecia, and myelosuppression. The study of cardiac toxicity, utilizing only noninvasive methods, indicated that epi-DXR also is cardiotoxic. The increase in the systolic time intervals after the first dose as well as after cumulative doses was slightly lower compared with that observed after DXR. Antitumor activity occurred in a variety of tumors including malignant melanoma, renal cancer, and rectal cancer, which are refractory to DXR. Present results suggest that further studies with epi-DXR are indicated.

View on publisher site
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 18 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 18 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 6 33%
Researcher 3 17%
Student > Bachelor 3 17%
Student > Master 2 11%
Student > Doctoral Student 1 6%
Other 1 6%
Unknown 2 11%
Readers by discipline Count As %
Chemistry 4 22%
Biochemistry, Genetics and Molecular Biology 3 17%
Pharmacology, Toxicology and Pharmaceutical Science 2 11%
Agricultural and Biological Sciences 2 11%
Immunology and Microbiology 1 6%
Other 2 11%
Unknown 4 22%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 May 2021.
All research outputs
#7,453,350
of 22,786,087 outputs
Outputs from Recent results in cancer research Fortschritte der Krebsforschung Progrès dans les recherches sur le cancer
#55
of 171 outputs
Outputs of similar age
#4,673
of 27,958 outputs
Outputs of similar age from Recent results in cancer research Fortschritte der Krebsforschung Progrès dans les recherches sur le cancer
#1
of 3 outputs
Altmetric has tracked 22,786,087 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 171 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.4. This one has gotten more attention than average, scoring higher than 53% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 27,958 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 28th percentile – i.e., 28% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 3 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them

This page is provided by Altmetric.